Can Med Spas Prescribe GLP-1s for Weight Loss? The 2026 Rules, Explained
Information current as of October 2026. General information only, not legal or medical advice. Med spa rules vary by state and are changing quickly, so review your specific setup with a healthcare attorney.
A med spa can offer GLP-1 weight loss, but the med spa itself never prescribes. A licensed prescriber does, after evaluating the patient, and only using a product that has a legal path to that patient. Most of the legal trouble med spas run into with semaglutide and tirzepatide comes from one of four places: who's actually prescribing, what's being dispensed, how it's advertised, and whether the spa's own structure is legal in its state.
We will cover the four places, and provide what changed in 2026 and a checklist for running a GLP-1 program that holds up.
1. Who can actually prescribe
A med spa is a business, not a license holder. Prescriptions come from individuals with prescriptive authority under state law:
Physicians (MD/DO) can prescribe GLP-1s in every state.
Nurse practitioners can prescribe in every state, but whether they need a collaborating or supervising physician depends on the state's practice rules.
Physician assistants can prescribe under whatever supervision or collaboration arrangement their state requires.
Registered nurses, aestheticians, and medical assistants cannot prescribe. Depending on the state, a trained RN may be allowed to administer an injection under a prescriber's order and supervision.
GLP-1s like semaglutide and tirzepatide aren't DEA-controlled substances, so there's no DEA registration layer the way there is for something like testosterone. The gating question is ordinary prescriptive authority plus the exam requirement.
The exam isn't optional. The American Med Spa Association (AmSpa) describes the baseline that applies everywhere: a prescriber-patient relationship has to be established, the prescriber performs an appropriate examination (usually called a "good faith exam"), reaches a diagnosis, and then orders treatment. Giving the injection itself can often be delegated to trained staff, but only under the prescriber's supervision, and sometimes under written protocols when the prescriber isn't on site. Whether the exam can happen over telehealth varies by state.
What doesn't hold up: a front desk "intake form" that leads straight to a vial, a standing order that treats every weight loss client the same, or a prescriber who signs charts for patients they never evaluated.
2. What you're dispensing matters as much as who prescribes it
This is where the rules moved the most over the last two years.
FDA-approved options
The approved GLP-1 options for chronic weight management now include injectables and, as of the past year, two once-daily pills:
Wegovy - semaglutide - Weekly injection - Approved for weight management
Wegovy pill - semaglutide - Daily pill - Approved December 2025
Zepbound - tirzepatide - Weekly injection - Approved for weight management
Foundayo - rforglipron - Daily pill - Approved April 1, 2026; no food or water timing restrictions
Saxenda liraglutide - Daily injection - Approved for weight management
Ozempic and Mounjaro contain the same active ingredients as Wegovy and Zepbound but are approved for type 2 diabetes, not weight management.
Compounded semaglutide and tirzepatide
During the 2022–2025 shortages, compounding pharmacies could legally make versions of these drugs because the approved products were on FDA's shortage list. That window is closed. FDA declared the tirzepatide shortage resolved in late 2024 and the semaglutide shortage resolved in February 2025, and the grace periods for compounders ended in the first half of 2025.
Where that leaves things in October 2026:
Compounding "essentially a copy" of an approved GLP-1 is no longer permitted. A compounded version now needs a patient-specific clinical reason the approved product won't work for that patient, not just a lower price or a preferred format.
Large-scale compounding is being shut down further. On April 30, 2026, FDA proposed formally excluding semaglutide, tirzepatide, and liraglutide from the list of substances that 503B outsourcing facilities can compound from bulk ingredients. In that analysis, FDA said supply issues, convenience, and cost don't count as clinical need. As of this writing, FDA hasn't announced a final decision, but the direction is clear.
Salt forms are off the table. FDA has said semaglutide sodium and semaglutide acetate are different active ingredients from what's in the approved drugs, and it knows of no lawful basis for compounding with them.
Some popular "next-gen" ingredients can't be compounded at all. FDA says retatrutide and cagrilintide can't be used in compounding under federal law, and it has warned sellers marketing GLP-1 ingredients as "for research purposes" or "not for human consumption."
Safety reports keep climbing. As of May 31, 2026, FDA had received 990 adverse event reports tied to compounded semaglutide and more than 730 tied to compounded tirzepatide, including dosing errors and doses beyond the approved labels. FDA notes these are likely underreported.
What this means for a med spa: if your weight loss program was built on compounded product sourced in volume, that model no longer has a legal basis. A compounded prescription today should be the exception, documented with a patient-specific reason, and filled by a properly licensed 503A pharmacy or registered 503B outsourcing facility.
3. How you talk about it
FDA has made GLP-1 marketing one of its most visible enforcement targets. It sent more than 55 letters to online sellers of compounded GLP-1s in September 2025, 30 warning letters to telehealth companies in March 2026, and another 25 in June 2026. Those letters went to telehealth companies, not med spas, but the violations they cite apply to anyone advertising these drugs:
Implying "sameness." Claims like "same active ingredient as Ozempic" or "generic Wegovy" for a compounded product. Compounded drugs aren't FDA-approved and aren't generics.
Calling compounded products FDA-approved. They aren't, even when the formula matches.
Obscuring the source. Branding product images with your own name or logo in a way that suggests your business made the drug.
Brand names carry their own risk. AmSpa's guidance is clear that you can't use Ozempic, Wegovy, Mounjaro, or Zepbound to market products you didn't obtain from the manufacturer, because that exposes the practice to trademark liability. Novo Nordisk and Eli Lilly have both taken legal action against med spas, clinics, and compounding pharmacies over how their products and ingredients were marketed.
Safer patterns: name the active ingredient, say plainly whether a product is compounded or FDA-approved, make clear a prescriber evaluation comes first, and keep before-and-after promises out of the ad copy.
4. Whether your med spa's structure is legal
Even with the right prescriber and the right product, the business itself has to be set up correctly. Many states follow the corporate practice of medicine doctrine, which limits who can own a business that provides medical services and bars non-physician owners from controlling clinical decisions. Illinois, for example, updated its guidance in late 2025 to restrict med spa ownership to physicians or full-practice-authority nurse practitioners. A non-physician owner in a strict state may need a management services structure instead of direct ownership, and that's a conversation for an attorney, not a template.
What changed in 2026
States have stopped treating med spas as an unregulated gray area. A few developments worth knowing:
State What happened
Indiana New law (SEA 282, effective July 1, 2026) requires med spas to register with the Medical Licensing Board starting January 1, 2027, name a "responsible practitioner" (physician, APRN, or PA), report serious adverse events, and follow tighter compounding rules. Fines up to $5,000 for operating unregistered.
Rhode Island The Medical Spas Safety Act requires a physician or certified nurse practitioner medical director at every med spa. Facility licensing rules were still pending as of August 2026.
Georgia The medical board's May 2026 position statement targets "matchmaker" arrangements where a physician signs on but provides no real oversight, and paid physician-matching services.
Oklahoma Nursing board guidance (March 2026) requires nurses doing aesthetic procedures to follow individualized provider orders, not standing orders.
New York A statewide sweep inspected more than 200 med spas and cited 87 for possible violations, including unlawful practice of medicine.
Texas "Jenifer's Law" (effective September 2025) tightened who can order and administer elective IV therapy, a sign of how quickly a single patient death can change the rules for a whole category.
Several other states, including Arizona, Florida, and Iowa, introduced med spa bills in 2026. Federal scrutiny is rising too: in April 2026, FDA issued its first-ever supply chain warning letter to a med spa, over Botox it couldn't trace to an authorized source.
Holland & Knight's August 2026 review of this activity found the same violations showing up again and again: unlicensed practice of medicine, oversight that exists on paper only, counterfeit or improperly compounded products, and deceptive marketing.
A checklist for a GLP-1 program that holds up
Name your prescribers and confirm their authority in your state, including any NP or PA supervision or collaboration requirements.
Make the exam real. Every patient gets an individualized evaluation by a prescriber before the first prescription, documented in the chart. Know whether your state allows it by telehealth.
Default to FDA-approved products. Use compounded GLP-1s only with a documented, patient-specific clinical reason.
Vet your pharmacy. Confirm 503A licensure or 503B registration, and ask how they source active ingredients. Avoid salt forms and anything labeled "research use only."
Write delegation down. Who administers injections, under whose supervision, and under which protocol.
Audit your marketing. No brand names for compounded product, no "FDA-approved" or "same as" claims, no hiding where the drug comes from.
Track outcomes and side effects, and report adverse events. FDA's MedWatch program takes reports from health care professionals.
Check your ownership structure against your state's corporate practice of medicine rules.
Watch your state. If you're in a state that passed or proposed a med spa law this year, assume registration, oversight, or reporting requirements are coming.
Where Doc Connect fits
Doc Connect is not a medical director service, and it doesn't replace one. If your state requires a medical director or responsible practitioner, that obligation stays with your practice.
What Doc Connect provides is physician review on a per-patient basis: you submit a client's information through your dashboard, and an independent physician licensed in that client's state conducts their own evaluation and decides whether to prescribe anything, and what, under their own license. Every step is logged, and approved prescriptions go to the pharmacy already on the client's file. For many practices, that's a way to add physician oversight to specific client requests without building a prescribing operation from scratch.
Frequently asked questions
Can a med spa owner who isn't a doctor offer GLP-1 weight loss?
In many states, yes, but not by prescribing it and often not by owning the medical side of the business directly. A licensed prescriber has to evaluate each patient and write the prescription, and corporate practice of medicine rules in your state determine how a non-physician owner can be involved.
Can a nurse practitioner prescribe semaglutide in a med spa?
Yes, NPs have prescriptive authority in every state. Whether they need a supervising or collaborating physician depends on the state.
Can a registered nurse prescribe GLP-1s?
No. An RN may be able to administer an injection under a prescriber's order and supervision, depending on the state, but can't prescribe.
Is compounded semaglutide illegal now?
Not entirely, but its lawful use is narrow. Compounding a copy of an approved drug is no longer permitted now that the shortages are over. A compounded version needs a patient-specific clinical reason, must come from a properly licensed pharmacy, and can't use salt forms. Mass-produced compounded GLP-1s no longer have a legal basis.
Can we use "Ozempic" or "Wegovy" in our ads?
Only for the actual branded product obtained from the manufacturer. Using brand names to market compounded product risks trademark claims and FDA misbranding concerns.
Do the new GLP-1 pills change anything for med spas?
They add FDA-approved options (the Wegovy pill and Foundayo) that don't require injections, which can make a compounded alternative even harder to justify on clinical grounds. The prescribing and exam rules are the same.
Can the good faith exam be done by telehealth?
In many states, yes, as long as it meets the state's standard for an appropriate exam. Rules vary, so confirm yours before building a remote intake flow.
Disclaimer: This article is general information for med spa owners and operators. It is not legal, medical, or compliance advice and does not account for your state's specific laws. Content is current as of October 2026; GLP-1 compounding rules and state med spa laws are changing quickly and may have changed since this was written. Talk to a healthcare regulatory attorney before launching or changing a weight loss program.
Sources: FDA: FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss; FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize; FDA: FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List; Federal Register notice, May 1, 2026 (91 FR 23431); FDA: FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s; Polsinelli: FDA Signals it Has No Appetite to Add Popular GLP-1 Drug Substances to the 503B Bulks List; AmSpa: Medical Weight Loss in a Med Spa Practice; AmSpa: Who Can Perform Semaglutide Treatments?; AmSpa: FDA Targets Telehealth Compounded GLP-1 Marketing in New Warning Letters; Holland & Knight: Medical Spa Compliance Under the Microscope; Indiana Capital Chronicle: Lawmakers finalize Indiana oversight plan for compounded drugs, medical spas; Georgia Composite Medical Board: IV Hydration Therapy Position Statement; Healio: FDA approves Foundayo, an oral GLP-1, for adults with obesity; ABA Business Law Today: Mitigating Risk in the Evolving Medspa Landscape